Fujifilm and Kodak watched the same asteroid coming. One is a $22 billion healthcare and semiconductor business. The other filed Chapter 11 in 2012.

Every conversation you have with an AI model runs on silicon that was polished flat by a chemical slurry, applied in layers measured in atoms.

The company with the world’s leading position in that slurry for copper wiring is not a chemicals giant you’ve heard of. It’s Fujifilm — which twenty-five years ago sold rolls of photographic film in green boxes in every pharmacy in Japan.

That sentence is the whole article. Everything below is the mechanism.

The Setup: A Perfect Business, With a Countdown Attached

Photographic film was one of the great business models of the twentieth century. Enormous barriers to entry — film is roughly a hundred precision-coated chemical layers on a plastic base, and almost nobody on earth could manufacture it. Consumable by design. Gross margins that read like a typo. Fujifilm and Kodak split a global duopoly and printed money.

Then digital arrived.

Both companies saw it coming — this is the part the Kodak folklore usually gets wrong. Kodak invented the digital camera in 1975 and held over a thousand digital imaging patents. Neither company was blindsided. They just answered a different question.

Kodak asked: how do we win in digital photography?

Fujifilm’s Shigetaka Komori, who became president in 2000, asked a question one level up: what are we, actually?

The answer he arrived at was not “a photography company.” It was something closer to: a company that is unusually good at advanced chemistry, precision thin-film coating, optics, and nanotechnology — and film happened to be one application of that.

That reframe, from product identity to capability identity, is the entire pivot. Everything else is execution.

The Collapse

The demand curve did not decline. It fell off a cliff.

Global color film demand peaked around 2000 at roughly 1.9 billion rolls and then collapsed by more than 90%. Fujifilm’s most profitable business — the one funding everything else — was evaporating at a pace that outran even its own pessimistic forecasts. Komori later admitted that when he announced his transformation plan in 2004 he still believed the company could restructure without deep job cuts, and that about two years in, the speed of the digital collapse forced him to accept he was wrong.

Kodak, meanwhile, spent those years trying to be a digital photography company. It succeeded, in the narrowest sense — and discovered what everyone in hardware eventually discovers, which is that digital cameras are a commodity business with commodity margins and no consumable attached. There is no film to sell you every weekend.

On January 19, 2012, Eastman Kodak filed for Chapter 11 listing debts of about $6.75 billion. Its patent portfolio, once valued internally in the billions, sold that year for roughly $525 million.

The Turn: Inventory the Capability, Then Go Find Markets

Fujifilm’s move had three parts, and the order matters.

First, an honest audit of what they owned. Komori put R&D to work systematically cataloguing every technology inside the company and mapping it against future market demand — a process that ran for roughly eighteen months. Not a brainstorm. An inventory.

What it surfaced was strange and specific. Photographic film depends on collagen (gelatin is a core structural component). It depends on antioxidant chemistry, because film degrades through oxidation and fading, and Fujifilm had spent decades learning to stop that. It depends on nanoparticle dispersion, and on coating layers with atomic-scale uniformity.

Collagen. Antioxidants. Nanodispersion. Precision coating.

Those are not photography technologies. Those are skincare, pharmaceuticals, medical imaging, and semiconductor manufacturing technologies that happened to be sitting inside a film company.

Second, VISION 75 — the restructuring. Launched in 2004, named for the company’s 75th anniversary, and blunt about its purpose: keep Fujifilm alive as a company of real scale. Film manufacturing capacity was cut roughly in half. Plants closed. Around 5,000 positions went, a genuinely painful move in a corporate culture built on long-tenure employment. Research divisions were consolidated into a central R&D organization so capabilities could be recombined across old business lines.

Critically, they cut nearly everywhere except R&D. The scientists who were going to find the new applications were the one thing not on the table.

Third, deployment — organic and acquired. Astalift, a skincare line built directly on the collagen and antioxidant research, launched in 2007. Toyama Chemical was acquired in 2008 to buy a real entry into pharmaceuticals rather than build one from zero. Imaging expertise was pushed into digital X-ray, endoscopy, CT and MRI. Coating expertise went into display materials and, eventually, the CMP slurries that semiconductor fabs use to planarize chips.

The Payoff

For the fiscal year ended March 31, 2026, Fujifilm Holdings reported revenue of about ¥3.36 trillion — roughly $22 billion — with net income of about ¥277 billion, both records. Healthcare alone crossed the ¥1 trillion mark and is now the company’s largest segment, driven by medical systems and a fast-growing biopharmaceutical contract manufacturing business with new large-scale facilities in Denmark. Electronics is riding semiconductor materials demand, including from AI chip production.

Photographic film still exists at Fujifilm. Instax, the instant camera line, is a genuinely good business. But the company that photography built now makes most of its money in medicine and materials science.

Kodak, from a nearly identical starting position, with a nearly identical warning, is a case study.

What Operators Can Steal From This

Your product is not your capability. Kodak defined itself by what it sold. Fujifilm defined itself by what it knew how to do. Only one of those definitions survives its category dying. Write down what your company is actually excellent at, in terms that never mention your product. That list is your real asset register.

Do the inventory before the strategy offsite. Eighteen months of cataloguing technologies against market demand is unglamorous and it’s the step almost everyone skips. Most companies pivot on a hunch about the market; Fujifilm pivoted on an audit of itself.

Cut everywhere except the thing that generates your future. Fujifilm halved film capacity and shed thousands of jobs while shielding R&D. When cuts come, the instinct is to protect revenue-producing units and squeeze the ones with no near-term return — which is precisely backwards if your revenue-producing unit is the thing that’s dying.

Winning the transition can still lose you the war. Kodak did build competitive digital cameras. It moved into the successor category and found the successor category had no margin in it. Before you race to win the next version of your market, check whether the next version is a business worth being in.

Denial is rarely the failure mode. Framing is. Both companies saw digital clearly, years out. The difference was the question they asked about it — and nobody ever calls a board meeting to review the question.